- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
Explore our full menu of advanced genomic testing solutions for solid tumors, hematologic malignancies, and immunohistochemistry. Powered by cutting-edge DNA and RNA sequencing technologies, our tests are designed to support precision diagnosis, prognostication, therapeutic decision-making, and clinical research.
Liquid Trace® is a comprehensive liquid biopsy assay that evaluates both cfDNA and cfRNA from blood samples, offering unmatched sensitivity in detecting actionable mutations, fusion transcripts, alternative splicing events, and gene expression profiles. With over 300 DNA and 1600 RNA targets, it delivers a complete molecular portrait of both solid tumors and hematologic malignancies.
Designed to overcome the limitations of traditional cfDNA-only liquid biopsies, Liquid Trace® enables earlier detection of cancer-associated molecular events and better monitoring of treatment response. It is particularly valuable when tissue samples are unavailable or difficult to obtain, providing clinicians with a powerful non-invasive diagnostic alternative.
Liquid biopsy alternative to bone marrow aspiration
This test is tailored for hematologic malignancies such as leukemias, lymphomas, myelomas, and VEXAS syndrome. It leverages cfDNA and cfRNA analysis from blood or CSF to detect a wide range of genomic abnormalities, including chromosomal translocations, gene amplifications, and fusion events, while also offering B-cell and T-cell clonality, HLA genotyping, and viral RNA detection (e.g., EBV, HTLV-1).
Liquid Trace® Hematology provides a minimally invasive alternative to bone marrow biopsy, significantly improving patient comfort and access to testing. With rapid turnaround and robust clinical utility, it supports diagnosis, therapy selection, MRD detection, and post-treatment monitoring with high sensitivity and accuracy.
Non-invasive molecular profiling for solid tumors
This version of Liquid Trace® is optimized for the analysis of solid tumors through blood or CSF samples, delivering detailed genomic insights without the need for tissue biopsy. It detects gene fusions, chromosomal abnormalities, exon skipping (e.g., MET exon 14), and expression levels of immunotherapy biomarkers like PD-L1 and HER2.
By combining cfDNA and cfRNA, this test offers a more complete view of tumor biology than conventional DNA-only panels. It enables clinicians to assess tumor dynamics over time, predict treatment response, and uncover biomarkers relevant to targeted therapy or immunotherapy—especially in cases where tumor tissue is inaccessible or insufficient.
GTC offers a full spectrum of NGS-based testing options for hematologic neoplasms, including leukemias, lymphomas, myelomas, and rare syndromes such as VEXAS. These tests analyze both DNA and RNA from bone marrow, peripheral blood, or fresh tissue to identify mutations, gene fusions, chromosomal abnormalities, viral associations, and immunologic profiles.
By integrating molecular findings with clinical relevance, these tests assist in accurate classification, risk stratification, and therapy guidance. The availability of both tissue-based and liquid biopsy formats enables flexibility for clinicians, while AI-enhanced analytics ensure rapid, informative, and actionable results.
Full-spectrum DNA/RNA profiling with expression analysis
This advanced profile combines next-generation DNA sequencing with RNA-based fusion and expression analysis for the most comprehensive view of hematologic malignancies. It is particularly useful for assessing complex cases, enabling fusion detection, gene expression classification, T-cell and B-cell clonality, and HLA genotyping all in one test.
Hematology Profile Plus™ is ideal for identifying therapeutic targets and monitoring disease evolution, relapse, or treatment resistance. Its broad gene coverage (>300 DNA, >1600 RNA) supports diagnosis, clinical decision-making, and even biomarker discovery for novel therapies such as ADCs and immunotherapies.
Targeted mutation profiling for hematologic neoplasms
This streamlined test focuses on DNA analysis of over 300 genes commonly mutated in hematologic malignancies, including MDS, MPN, CHIP, and others. It supports differential diagnosis and delivers actionable genomic insights quickly and cost-effectively, using bone marrow, blood, or tissue samples.
Hematology Profile™ is ideal for routine molecular classification and initial workup of hematologic cancers. Despite its narrower scope compared to the Plus version, it still covers essential prognostic markers and supports decisions on therapy initiation or escalation.
GTC provides solid tumor profiling through both targeted DNA testing and integrated DNA/RNA panels. These tests assess molecular alterations relevant to prognosis and treatment, including MSI, TMB, CNVs, SNVs, fusions, and immunotherapy markers.
By offering flexible test formats and specimen types, including FFPE tissue and liquid biopsy, GTC enables comprehensive tumor profiling even in limited sample scenarios. The addition of IHC testing for PD-L1 and other targets enhances the clinical value of these assays.
Pan-cancer DNA and RNA testing with high clinical utility
Solid Tumor Profile Plus™ evaluates >400 DNA and >1600 RNA targets, detecting single nucleotide variations, gene fusions, copy number changes, alternative splicing, and immunotherapy-related markers. It also includes viral detection (HPV, EBV, etc.) and TMB/MSI analysis.
This test is designed for maximum diagnostic yield across all solid tumor types and is especially useful for identifying candidates for targeted or immune-based therapies. The RNA component allows for precise expression-level evaluation and uncovering rare fusion events, enhancing its predictive power.
DNA-based testing for core tumor mutations
This DNA-only test analyzes 434 genes to detect key tumor mutations and genomic instabilities such as MSI, TMB, and HRD. It is suitable for small or limited samples and offers fast turnaround, making it a practical solution for routine oncologic care.
Solid Tumor Profile™ supports therapy selection and prognosis by identifying known pathogenic variants, chromosomal abnormalities, and therapeutic resistance markers. It offers a balance between broad molecular insight and efficiency.
Protein-level biomarker testing for tumor classification
GTC’s IHC testing panel includes a wide range of stains used for diagnostic clarification, subtyping, and therapy selection in solid and hematologic tumors. It complements molecular tests by confirming protein expression and localization within the tumor tissue.
IHC can be ordered as a standalone service or added to NGS panels. It provides critical data on markers like PD-L1, CLDN18, FOLR1, and others, helping clinicians determine eligibility for targeted therapies or immunotherapy strategies.
